Sarepta New Logo - Search News

Sarepta Therapeutics Stock Sinks

Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure. The pharmaceutical firm said that "acute liver injury is a known possible side effect of Elevidys.

Markets Insider · 11h

Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy,

MarketWatch on MSN · 1d

Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

Sarepta falls after notifying of patient death following treatment with Elevidys

Therapeutics are down 24.95, or 25%, to $76.40 in pre-market trading after the company shared a safety update related ...

pharmaphorum7y

Sarepta announces Allergan veteran as next CEO

Sarepta has announced former Allergan president Doug Ingram will be its new CEO. Ingram will be the company's third CEO in less than three years, but his experience could help it maximise the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Sarepta Therapeutics Stock Sinks

Trending now